BB Biotech (0JYO) Share Forecast & Price Target
0JYO Analyst Ratings
There are no analyst ratings in the last 3 months.
0JYO Stock 12 Month Forecast
There are no analyst price targets in the last 3 months.
Detailed List of Analyst Forecasts
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Nicolas Pauillac | Kepler Capital | CHF 66→CHF 73 | buy | 42.58%Upside | Reiterated | 04/24/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Nicolas Pauillac | 04/24/26 | CHF 66→CHF 73 | buy | 42.58%Upside | Reiterated | Kepler Capital |
Best Analysts Covering BB Biotech
Copying Nicolas Pauillac's trades and holding each position for 3 Months would result in 46.15% of your transactions generating a profit, with an average return of +1.21% per trade.
Copying Nicolas Pauillac's trades and holding each position for 1 Year would result in 69.23% of your transactions generating a profit, with an average return of +16.98% per trade.
Copying Nicolas Pauillac's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +41.37% per trade.
0JYO Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 1 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 1 | 0 | 0 | 0 | 0 |
In the current month, 0JYO has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 0JYO average Analyst price target in the past 3 months is ―.
0JYO Financial Forecast
0JYO Earnings Forecast
Next quarter’s earnings estimate for 0JYO is CHF 3.17 with a range of ― to ―. The previous quarter’s EPS was CHF 3.17. Its overall industry beat the EPS estimate 50.49% of the time in the past 12 months.
0JYO Sales Forecast
Next quarter’s sales forecast for 0JYO is CHF 94.46M with a range of ― to ―. The previous quarter’s sales results were CHF 94.46M. Its overall industry beat sales estimates 63.25% of the time in the past 12 months.